ArticleJournal of neurology2025
Chemotherapy-induced polyneuropathy: diagnostic challenges and the potential of neurofilament as a biomarker for sensory disorders: the CONKO 023-ChemTox Trial.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Longitudinal plasma neurofilament light chain and patient-reported outcomes as complementary markers of vincristine-associated peripheral neuropathy in adults with lymphoma: a cohort study.Journal of neurology · 2026Observational
- Longitudinal plasma neurofilament light chain and patient-reported outcomes as complementary markers of vincristine-associated peripheral neuropathy in adults with lymphoma: a cohort study.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy-induced polyneuropathy (CIPN) is a prevalent side effect impairing patients' quality of life, often manifesting as dysesthesia or pain in extremities. To minimize therapy-related side effects as well as to improve quality of life, modern approaches grow increasingly more relevant. We conducted a longitudinal, prospective study to examine patients with lymphoma, leukemia, or gastrointestinal malignancies receiving continuous and temporary treatment up to five times over a 12- to 24-month period, beginning prior to chemotherapy. Assessments included comprehensive questionnaires, clinical neurological and electroneurographic examinations and measurements of neurofilament light chain (NFL). One hundred eight patients were enrolled with fifty-six patients having undergone all examinations both before and after chemotherapy. Data showed a significant rise of the mean Total Neuropathy Score (TNSr) after chemotherapy. Results revealed that approximately 75% of patients experienced CIPN. Continuous chemotherapy was associated with a steady increase in TNSr. Older patients, often with pre-existing and underdiagnosed neuropathy, were more frequently and more severely affected. According to medical records, where diagnostics were primarily based on patients' subjective information, even moderate cases were frequently underdiagnosed. A moderate correlation was observed between the increase in NfL and changes in TNSr (r = 0.385, p = 0.004). Patients with cancer affecting the central nervous system (CNS) showed elevated baseline NFL levels. In contrast to non-responders, NFL decreased in patients who responded well to therapy. In conclusion, data underline the necessity of improved diagnostic accuracy of CIPN and support the potential of NFL as a biomarker for its detection. Further investigations should assess its potential in daily oncological routine.Trial registration number: EA2/167/21 (date of registration: 12.08.2021).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.